Literature DB >> 8371919

Long-term efficacy of argon laser trabeculoplasty. A 10-year follow-up study.

B J Shingleton1, C U Richter, S K Dharma, L Tong, A R Bellows, B T Hutchinson, R J Glynn.   

Abstract

PURPOSE: Argon laser trabeculoplasty (ALT) is commonly used in the treatment of open-angle glaucoma. Varying success rates in lowering intraocular pressure (IOP) and controlling glaucoma are reported in studies with follow-up periods from 1 to 5 years, and few reports are available with follow-up to 10 years. The authors retrospectively reviewed the efficacy of ALT in patients followed up to 10 years.
METHODS: Ninety-three patients with open-angle glaucoma underwent 360 degrees ALT. Mean follow-up was 52 +/- 43 months (mean +/- standard deviation; range, 1-132 months). Successful treatment at the time of final follow-up was defined as a decrease in IOP of 3 mmHg or greater from pretreatment level, IOP of 19 mmHg or less, stable visual field, stable optic nerve, and no further laser or surgical intervention.
RESULTS: The decrease in IOP was 8.9 +/- 5.4 mmHg at 1 year, 10.0 +/- 4.2 mmHg at 5 years, and 8.9 +/- 5.2 mmHg at 10 years. The probability of success at 1 year was 77%, at 5 years 49%, and at 10 years 32%. Failure was most common in the first year after treatment (23%), and thereafter failure occurred at a rate of 5% to 9% per year. The mean decrease in IOP for all 93 eyes at time of maximum follow-up was 6.1 +/- 7.1 mmHg.
CONCLUSION: Argon laser trabeculoplasty is an effective means for reducing IOP in many patients followed for an extended time. However, up to one half of eyes within 5 years of ALT and two thirds of eyes within 10 years may require additional laser or surgical intervention for glaucoma control.

Entities:  

Mesh:

Year:  1993        PMID: 8371919     DOI: 10.1016/s0161-6420(93)31480-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  15 in total

1.  Membrane formation in the chamber angle after failure of argon laser trabeculoplasty: analysis of risk factors.

Authors:  T Koller; J Stürmer; C Remé; B Gloor
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

2.  Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial.

Authors:  W G Hodge; K F Damji; W Rock; R Buhrmann; A M Bovell; Y Pan
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

3.  Efficacy of argon laser trabeculoplasty: 3-year preliminary results of a prospective placebo-controlled study.

Authors:  C Ustundag; M Diestelhorst
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-06       Impact factor: 3.117

4.  Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.

Authors:  A L Robin; R Ritch; D Shin; B Smythe; T Mundorf; R P Lehmann
Journal:  Trans Am Ophthalmol Soc       Date:  1995

5.  Sustained release of matrix metalloproteinase-3 to trabecular meshwork cells using biodegradable PLGA microparticles.

Authors:  Sanja Turturro; Suhair Sunoqrot; Hongyu Ying; Seungpyo Hong; Beatrice Y J T Yue
Journal:  Mol Pharm       Date:  2013-07-18       Impact factor: 4.939

6.  The effect of argon laser trabeculoplasty on the blood-aqueous barrier and intraocular pressure in human glaucomatous eyes treated with diclofenac 0.1%.

Authors:  M Diestelhorst; D Thull; G K Krieglstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-09       Impact factor: 3.117

7.  Role of argon laser trabeculoplasty as primary and secondary therapy in open angle glaucoma in Indian patients.

Authors:  H C Agarwal; R Sihota; C Das; T Dada
Journal:  Br J Ophthalmol       Date:  2002-07       Impact factor: 4.638

Review 8.  The pathophysiology and treatment of glaucoma: a review.

Authors:  Robert N Weinreb; Tin Aung; Felipe A Medeiros
Journal:  JAMA       Date:  2014-05-14       Impact factor: 56.272

9.  Pneumatic trabeculoplasty vs latanoprost as adjunctive therapy to timolol in primary open-angle glaucoma or ocular hypertension.

Authors:  M G Uva; A Longo; M Reibaldi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-02-27       Impact factor: 3.117

10.  Experience with argon laser trabeculoplasty in Nigerians.

Authors:  Olusola Olawoye; Adelina A Ashaye; Tarela F Sarimiye
Journal:  Ghana Med J       Date:  2017-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.